Coinfection means living with both HIV and the hepatitis C virus (HCV) — common because both travel through blood. About 21% of people with HIV in the U.S. also have hepatitis C, rising to 62–80% among people with HIV who inject drugs[1][2]. It matters because HIV accelerates liver damage — and it is fixable: hepatitis C is curable in 8–12 weeks with oral pills[3].
How common coinfection is, and why the two viruses travel together
The number you will see most often is about 21%. NIH states plainly that “about 21% of people with HIV in the United States also have hepatitis C”[2], and CDC's own page traces the figure to testing data: “in 2009, approximately 21% of adults with HIV who were tested for past or present HCV infection tested positive, although coinfection prevalence varies substantially according to risk group”[1]. HRSA rounds it for plain language: “approximately one in five people living with HIV… is coinfected with the hepatitis C virus”[4]. If you have read “about 25%” somewhere, that figure is not what CDC, NIH, or HRSA publish.
The rate is dramatically higher in one group. Among people with HIV who inject drugs, CDC estimates coinfection at 62% to 80%[1], and HIV.gov puts it at “nearly 75% of people living with HIV who report a history of injection drug use”[3]. That concentration is about shared equipment and access to services — not about the people.
“Because both HIV and HCV can spread via blood, a major risk factor for both HIV and HCV infection is injection drug use,” and “in the United States, HCV is spread mainly by sharing needles or other injection drug equipment”[2]. Everything that carries blood — syringes, cookers, cotton, water — can carry both.
Sexual transmission of hepatitis C is less common but real. CDC notes that “sexual transmission can happen among MSM with HIV, especially among those who have unprotected anal intercourse, use sex toys, or use non-injection drugs”[1]. HIV.gov adds that HCV sexual transmission “is most likely to happen during anal intercourse among men who have sex with men, particularly for the receptive partner,” and that coinfection also increases the chance of passing hepatitis C perinatally[3].
Why coinfection accelerates liver disease
Hepatitis C damages the liver slowly on its own: HHS guidelines note that “approximately one-third of patients with chronic HCV infection progress to cirrhosis at a median time of <20 years,” and that “the rate of progression increases with older age, alcoholism, male sex, and HIV infection”[5].
The quantified difference is the headline. “A meta-analysis found that patients with HCV/HIV coinfection had a threefold greater risk of progression to cirrhosis or decompensated liver disease than patients with HCV mono-infection,” with even greater risk at low CD4 counts[5]. HIV treatment helps but does not erase the difference: ART “appears to slow the rate of HCV disease progression… [but] the rate of disease progression continues to exceed that observed in patients without HIV”[5]. CDC says it in one line: “HCV-related liver injury progresses more rapidly among people coinfected with HIV”[1], and HIV.gov notes that viral hepatitis “progresses faster and causes more liver-related health problems like liver cirrhosis, liver cancer, and end-stage liver disease among people living with HIV”[3].
The takeaway is not fear — it is timing. Faster progression is exactly why testing and curing hepatitis C early is worth pushing for.
Getting tested: two steps, and who needs it
The recommendation is universal. “Every person who has HIV should get tested for HCV,” with more frequent testing for people with ongoing exposure and testing during each pregnancy[2]. HIV.gov: “everyone with HIV should be tested for HBV and HCV when they are first diagnosed with HIV and begin treatment,” and annually if ongoing risk factors exist[3]. CDC separately recommends one-time hepatitis C testing for all adults 18 and older, testing in each pregnancy, and periodic testing for people with risk factors “like those who have HIV or share injection drug use equipment”[1].
Expect two steps: an HCV antibody test first, then a confirmatory HCV RNA test — because a positive antibody test alone does not mean you have hepatitis C now. It may reflect a past infection that cleared[2]. Ask for the RNA result before drawing any conclusions.
Hepatitis C is curable — including for people with HIV
This is the part that has changed everything. HHS guidelines state that “all patients with HCV/HIV coinfection are candidates for curative HCV treatment,” and that people with coinfection “can achieve sustained virologic response (HCV cure) at rates comparable to those in patients with HCV mono-infection”[5]. AASLD/IDSA guidance is equally direct: people with HIV/HCV coinfection “should be treated and retreated the same as persons without HIV infection, after recognizing and managing interactions with antiretroviral medications”[6]. In plain terms, HIV.gov says these treatments “cure about 97% of people, including those living with HIV, with just 8-12 weeks of oral therapy (pills)”[3], and NIH puts it as “more than 95% of people within 12 weeks”[2].
Two direct-acting antiviral (DAA) regimens carry the strongest coinfection data:
- Glecaprevir/pibrentasvir — in EXPEDITION-2, 8 weeks for adults with coinfection and no cirrhosis and 12 weeks for those with compensated cirrhosis produced an overall SVR12 of 98% (136/136 without cirrhosis on 8 weeks; 14/15 with compensated cirrhosis on 12 weeks). Dosing is three coformulated tablets once daily[7].
- Sofosbuvir/velpatasvir — 12 weeks in 106 adults with coinfection on stable ART produced an SVR12 of 95%. In the MINMON study, SVR12 was 94.6% among participants with HIV versus 95.3% among those without[6].
Other regimens have coinfection data too: elbasvir/grazoprevir for 12 weeks, SVR12 96% (210/218); ledipasvir/sofosbuvir for 12 weeks, SVR12 96% (321/335) in ION-4; and sofosbuvir/velpatasvir/voxilaprevir after prior DAA failure, SVR12 82% intention-to-treat and 93% per protocol in RESOLVE[7]. One caution: the ultra-short courses used for some people without HIV do not apply here — “a shortened treatment course for HIV/HCV-coinfected persons is not recommended at this time”[7].
Drug–drug interactions: the one real complication
The main clinical task is making sure the hepatitis C pills and the HIV pills get along. HHS guidelines state that “several ARV drugs and HCV DAAs have the potential for clinically significant pharmacokinetic drug–drug interactions when used in combination,” and that “before starting HCV therapy, the ART regimen may need to be modified to reduce the drug–drug interaction potential” — with specific pairings listed in the guidelines' Table 18[5]. AASLD/IDSA echo that treatment “requires continued awareness and attention to the complex drug-drug interactions that can occur between DAAs and antiretroviral medications”[7]. NIH's plain-language version: “some HIV and HCV medicines cannot be safely used together because of drug-drug interactions”[2].
What that means for you: bring a complete list of everything you take — HIV medicines, other prescriptions, over-the-counter drugs, supplements, and antacids — to the visit where hepatitis C treatment is planned, and ask your prescriber to check it against HHS Table 18. Sometimes a small change to the ART regimen for the 8–12 weeks of hepatitis C treatment is all that is needed. HIV.gov also recommends care from providers experienced in both conditions, and notes that coinfection “can be effectively treated in most people” even though people with HIV “are at greater risk for complications and death from HCV infection”[3].
Cost is often solvable: “the majority of states, plus Washington, D.C. and Puerto Rico, make DAA therapies available to coinfected individuals through the Ryan White HIV/AIDS Program Part B AIDS Drug Assistance Program”[4]. Curing hepatitis C is prevention as well as treatment: one cure removes a transmissible infection from the picture for good, and it protects the liver you will need for decades.
Florida: 541 co-occurring diagnoses and a rising acute hepatitis C count
Florida DOH counted 541 adults with co-occurring HIV and hepatitis C diagnoses in 2023 (441 men, 100 women). Among the men, 63% of HIV diagnoses were attributed to male-to-male sexual contact, 8% to injection drug use, and 11% to both; among the women, 64% to heterosexual contact and 35% to injection drug use — clear evidence that coinfection in Florida is not a single-route story[8]. Separately, 667 people with HIV in Florida were diagnosed with acute hepatitis C in 2023, and their care outcomes were slightly better than the state average (83% in care, 77% retained, 76% suppressed, versus 79%/73%/70% for all 128,497 people with HIV in Florida) — consistent with coinfection being caught mostly among people already engaged in HIV care, and a reminder of who is being missed[8].
The hepatitis C trend line is going the wrong way: Florida reported 1,435 acute hepatitis C cases in 2023 (6.3 per 100,000), up from 616 cases (2.9 per 100,000) in 2019 — more than a doubling in five years[9]. Miami's IDEA Exchange is the clearest Florida model of an integrated answer, offering hepatitis C testing and treatment alongside syringe services, HIV prevention and care, and wound care in one place[10].
Related questions
How many people with HIV also have hepatitis C?
About 21% of people with HIV in the United States — roughly one in five, per CDC, NIH, and HRSA. Among people with HIV who inject drugs, CDC estimates coinfection at 62% to 80%.
Can hepatitis C be cured if you have HIV?
Yes. HHS guidelines state that all people with HIV/HCV coinfection are candidates for curative hepatitis C treatment and achieve cure rates comparable to people without HIV. Oral direct-acting antivirals take 8 to 12 weeks: glecaprevir/pibrentasvir reached 98% SVR12 in EXPEDITION-2, and sofosbuvir/velpatasvir reached 95% over 12 weeks.
Will hepatitis C treatment interfere with my HIV medication?
It can, which is why the regimens are chosen together. HHS guidelines note clinically significant interactions between some HIV medicines and some hepatitis C direct-acting antivirals and list specific pairings in Table 18; sometimes the ART regimen is adjusted before hepatitis C treatment starts. Bring a full list of everything you take to that visit.
Why does hepatitis C get worse faster in people with HIV?
A meta-analysis cited in HHS guidelines found a threefold greater risk of progression to cirrhosis or decompensated liver disease among people with HIV/HCV coinfection compared with hepatitis C alone, with higher risk at low CD4 counts. HIV treatment slows progression but does not fully close the gap — which is why early hepatitis C testing and cure matter.
Related from RiseUpToHIV
References & Sources
- CDC — Viral Hepatitis Among People with HIV. The ~21% coinfection figure from 2009 testing data, 62–80% among people with HIV who inject drugs, sexual transmission among MSM, faster liver injury, and CDC's hepatitis C testing recommendations. ↩ ↩ ↩ ↩ ↩ ↩
- NIH HIVinfo — HIV and Hepatitis C. "About 21% of people with HIV in the United States also have hepatitis C," shared blood-borne routes, universal HCV testing for people with HIV, the antibody-then-RNA sequence, cure in more than 95% within 12 weeks, and drug–drug interaction warning. ↩ ↩ ↩ ↩ ↩ ↩ ↩
- HIV.gov — Hepatitis B & C. Nearly 75% coinfection among people with HIV reporting injection drug use, sexual and perinatal transmission, faster liver disease, testing at diagnosis and annually, cure of about 97% in 8–12 weeks, and the need for experienced providers. ↩ ↩ ↩ ↩ ↩ ↩ ↩
- HRSA Ryan White HIV/AIDS Program — HIV and Hepatitis C Coinfection. "Approximately one in five people living with HIV" is coinfected, and DAA availability through Ryan White Part B AIDS Drug Assistance Programs in most states. ↩ ↩
- HHS/NIH Clinicalinfo — Hepatitis C Virus/HIV Coinfection (Adult and Adolescent ARV Guidelines). One-third progressing to cirrhosis in a median of under 20 years, the threefold greater risk with coinfection, ART slowing but not equalizing progression, all people with coinfection being candidates for cure, and drug–drug interactions with Table 18. ↩ ↩ ↩ ↩ ↩
- AASLD/IDSA HCV Guidance — Persons With HIV/HCV Coinfection. Recommendation to treat and retreat the same as people without HIV after managing ARV interactions, and sofosbuvir/velpatasvir SVR12 of 95% (plus MINMON results). ↩ ↩
- AASLD/IDSA HCV Guidance — Unique Populations section (PDF). EXPEDITION-2 glecaprevir/pibrentasvir SVR12 of 98% and dosing, elbasvir/grazoprevir, ledipasvir/sofosbuvir and RESOLVE results, the statement against shortened courses in coinfection, and the drug-interaction caution. ↩ ↩ ↩ ↩
- Florida DOH — State of the HIV Epidemic, 2023. 541 adults with co-occurring HIV and hepatitis C diagnoses in 2023 by sex and transmission category, and the care continuum for the 667 people with HIV diagnosed with acute HCV versus the statewide figures. ↩ ↩
- CDC — Viral Hepatitis Surveillance 2023, Table 3.1 (acute hepatitis C by state). Florida's acute hepatitis C cases rising from 616 (2.9 per 100,000) in 2019 to 1,435 (6.3 per 100,000) in 2023. ↩
- University of Miami Miller School of Medicine — IDEA Exchange. Integrated Florida model offering hepatitis C testing and treatment alongside syringe services, HIV prevention and care, and wound care. ↩
Community publications like POZ, Positively Aware, and TheBody inform framing and lived-experience context on RiseUpToHIV. Every clinical, epidemiological, or public-health claim above is anchored to a primary source.